Brand Name Drug Negotiations Status
The pCPA is a part of the overall Canadian drug approval and reimbursement process. It starts with regulatory approval through Health Canada where drugs are evaluated for efficacy, quality and safety. Following a positive approval from Health Canada, all drugs then go through a health technology assessment for clinical and cost-effectiveness. In Canada there are two review boards, the Canadian Agency for Drugs and Technologies in Health (CADTH) which reviews common drugs through the Common Drug Review (CDR) and oncology drugs through the Pan-Canadian Oncology Drug Review (pCODR). In Quebec, drugs are reviewed through l’Institut national d’excellence en santé et en services sociaux (INESSS). For the majority of new drugs, the pCPA negotiation process begins once a recommendation is published by CADTH and/or INESSS.
| Product | Manufacturer | Status | Indication |
|---|---|---|---|
| Cablivi (caplacizumab) | SANOFI-AVENTIS | Negotiations were not pursued | acquired thrombotic thrombocytopenic purpura (aTTP) |
| Rituxan SC (rituximab) | Hoffmann-La Roche | Active Negotiation | Chronic Lymphocytic Leukemia |
| Tecentriq & Avastin (Atezolizumab & Bevacizumab) | HOFFMANN-LA ROCHE LIMITED | Negotiations were not pursued | Non-Squamous Non-Small Cell Lung Cancer |
| Aimovig (erenumab) | NOVARTIS PHARMACEUTICALS CANADA INC | Under consideration for negotiation | migraine, chronic |
| Vocabria and Cabenuva (cabotegravir and rilpivirine) | VIIV HEALTHCARE ULC | Active Negotiation | HIV Infection |
| Mayzent (siponimod) | NOVARTIS PHARMACEUTICALS CANADA INC | Under consideration for negotiation | Secondary progressive multiple sclerosis (SPMS) |
| Vascepa (icosapent ethyl) | HLS THERAPEUTICS INC | Under consideration for negotiation | Ischemic events in statin-treated patients |
| Stelara (ustekinumab) | Janssen Inc. | Under consideration for negotiation | Ulcerative Colitis |
| Soliris (eculizumab) | Alexion Pharma GMBH | Under consideration for negotiation | Neuromyelitis optica spectrum disorder (NMOSD) |
| Darzalex SC (Daratumumab ) | Janssen Inc. | Active Negotiation | Multiple Myeloma |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Concluded with an LOI | Peripheral T-Cell Lymphoma |
| Cuvposa (Glycopyrrolate) | Medexus Inc. | Under consideration for negotiation | chronic severe drooling, neurologic (pediatric) |
| Xospata (Gilteritinib) | Astellas Pharma Inc. | Active Negotiation | Acute Myeloid Leukemia |
| Aermony Respiclick (fluticasone propionate) | Teva Canada Limited | Active Negotiation | Asthma |
| Kisqali (ribociclib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Advanced or Metastatic Breast Cancer |
| Kalydeco (ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Active Negotiation | cystic fibrosis in patients with CFTR gating mutations or the R117H gating mutation |
| Orkambi (lumacaftor/ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Active Negotiation | Cystic Fibrosis, F508del CFTR mutation |
| Contrave (naltrexone hydrochloride and bupropion hydrochloride) | Bausch Health, Canada Inc. | Negotiations were not pursued | Chronic weight management |
| Nubeqa (Darolutamide) | Bayer Inc. | Under consideration for negotiation | non-metastatic castrate resistant prostate cancer |
| Erleada (apalutamide) | Janssen Inc. | Active Negotiation | Metastatic Castration-Sensitive Prostate Cancer |
| Cabometyx (cabozantinib) | Ipsen Biopharmaceuticals | Under consideration for negotiation | hepatocellular carcinoma |
| Crysvita (burosumab) | Ultragenyx Canada Inc. | Active Negotiation | X-Linked Hypophosphatemia |
| Entyvio (SC) (vedolizumab) | Takeda Canada Inc. | Active Negotiation | Ulcerative Colitis |
| Dupixent (dupilumab) | Sanofi Genzyme | Active Negotiation | Atopic dermatitis |
| Beovu (brolucizumab) | Novartis Pharma Canada Inc. | Under consideration for negotiation | Age-Related Macular Degeneration |
| Benlysta (belimumab) | GlaxoSmithKline | Under consideration for negotiation | Systemic lupus erythematosus |
| Kisqali (with fulvestrant) (ribociclib with fulvestrant) | Novartis Pharma Canada Inc. | Concluded with an LOI | Advanced or Metastatic Breast Cancer |
| Allerject (epinephrine) | Kaleo Inc | Concluded with an LOI | For the emergency treatment of severe acute allergic reactions (anaphylaxis). |
| Avsola (infliximab) | Amgen Canada Inc. | Active Negotiation | Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn’s disease and Ulcerative Colitis |
| Nivestym (filgrastim) | Pfizer Canada ULC | Concluded with an LOI | Prevention or treatment of neutropenia in various indications |
| Ziextenzo (pegfilgrastim) | Sandoz Canada | Concluded with an LOI | febrile neutropenia in non-myeloid malignancies |
| Kanjinti (trastuzumab) | Amgen Canada Inc. | Concluded with an LOI | early breast cancer/metastatic breast cancer/metastatic gastric cancer |
| Envarsus PA (tacrolimus) | Paladin Labs Inc. | Concluded with an LOI | prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients |
| Onstryv (safinamide) | Valeo Pharma Inc. | Under consideration for negotiation | Parkinson's Disease |
| Monoferric (iron (iii) isomaltoside 1000) | Pharmacosmos A/S | Active Negotiation | iron deficiency anemia |
| Lokelma (sodium zirconium cyclosilicate) | AstraZeneca Canada Inc. | Negotiations were not pursued | hyperkalemia |
| Taltz (ixekizumab) | Eli Lilly Canada Inc. | Under consideration for negotiation | Ankylosing spondylitis |
| Vyndaqel (tafamidis) | Pfizer Canada ULC | Active Negotiation | transthyretin-mediated amyloidosis |
| Rinvoq (upadacitinib) | AbbVie Corporation | Under consideration for negotiation | Subacute and chronic inflammatory joint diseases |
| Lonsurf (trifluridine/tipiracil) | Taiho Pharma Canada Inc. | Active Negotiation | metastatic Gastric Cancer |
| Riximyo (rituximab) | Sandoz Canada | Concluded with an LOI | Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma |
| Ruxience (rituximab) | Pfizer Canada ULC | Concluded with an LOI | Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA) |
| Lutathera (lutetium 177 dotatate) | Advanced Accelerator Applications | Concluded with an LOI | Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) |
| Baqsimi (glucagon) | Eli Lilly Canada Inc. | Under consideration for negotiation | severe hypoglycemia |
| Admelog (insulin lispro) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Lorbrena (lorlatinib) | Pfizer Canada ULC | Negotiations were not pursued | Non-Small Cell Lung Cancer (ALK+) |
| Rydapt (midostaurin) | Novartis Pharmaceuticals Canada Inc. | Negotiations were not pursued | Systemic Mastocytosis |
| Mylotarg (gemtuzumab ozogamicin) | Pfizer Canada ULC | Concluded with an LOI | Acute Myeloid Leukemia |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Active Negotiation | renal cell carcinoma |
| Nerlynx (neratinib) | Knight Therapeutics | Negotiations were not pursued | Hormone Receptor-Positive Breast Cancer |
| Cimzia (certolizumab pegol) | UCB Canada Inc. | Active Negotiation | Psoriasis, moderate to severe plaque |
| Takhzyro (lanadelumab) | Shire Pharma Canada ULC | Active Negotiation | Hereditary Angioedema |
| Revestive (teduglutide) | Shire Pharma Canada ULC | Active Negotiation | Short Bowel Syndrome (SBS) |
| Verkazia (cyclosporine) | Santen Incorporated | Active Negotiation | severe vernal keratoconjunctivitis |
| Lonsurf (trifluridine/tipiracil) | Taiho Pharma Canada Inc. | Negotiations were not pursued | Metastatic Colorectal Cancer |
| Mezera (mesalazine) | AVIR Pharma Inc. | Concluded with an LOI | Ulcerative Colitis |
| Kadcyla (trastuzumab emtansine) | Hoffmann-La Roche | Active Negotiation | early breast cancer |
| Darzalex (daratumumab) | Janssen Inc. | Under consideration for negotiation | Multiple Myeloma |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Squamous Non-Small Cell Lung Cancer |
| Tecentriq (atezolizumab) | Hoffmann-La Roche | Under consideration for negotiation | Small Cell Lung Cancer |
| Lynparza (olaparib) | AstraZeneca Canada Inc. | Active Negotiation | Ovarian Cancer |
| Trintellix (vortioxetine) | Lundbeck Canada Inc. | Active Negotiation | Major Depressive Disorder |
| Xultophy (insulin degludec/liraglutide) | Novo Nordisk Canada Inc. | Active Negotiation | Diabetes Mellitus, Type 2 |
| Dovato (dolutegravir/lamivudine) | ViiV Healthcare | Concluded with an LOI | HIV Infection |
| Iluvien (fluocinolone acetonide) | Knight Therapeutics | Negotiations were not pursued | Diabetic Macular Edema |
| Emerade (epinephrine bitartrate) | Bausch Health, Canada Inc. | Concluded with an LOI | For the emergency treatment of severe acute allergic reactions (anaphylaxis). |
| Bosulif (bosutinib) | Pfizer Canada ULC | Concluded with an LOI | Chronic Myeloid Leukemia |
| Olumiant (baricitinib) | Eli Lilly Canada Inc. | Active Negotiation | Subacute and chronic inflammatory joint diseases |
| Orfadin Oral Suspension (nitisinone) | Sobi Canada Inc. | Concluded without agreement | Hereditary Tyrosinemia Type 1 |
| Onpattro (patisiran) | Alnylam Netherlands B.V. | Active Negotiation | hereditary transthyretin-mediated amyloidosis |
| Tegsedi (inotersen) | Akcea Therapeutics Inc. | Concluded with an LOI | hereditary transthyretin-mediated amyloidosis |
| Truxima (rituximab) | Teva Canada Limited | Concluded with an LOI | Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma |
| Vitrakvi (larotrectinib) | Bayer Inc. | Negotiations were not pursued | Neurotrophic Tyrosine Receptor Kinase (NTRK) Locally Advanced or Metastatic Solid Tumours |
| Pomalyst (pomalidomide) | Celgene Inc. | Under consideration for negotiation | Multiple Myeloma (Relapsed) |
| Idhifa (enasidenib) | Celgene Inc. | Under consideration for negotiation | Acute Myeloid Leukemia |
| Revlimid (lenalidomide) | Celgene Inc. | Concluded with an LOI | Multiple Myeloma |
| Sublocade (buprenorphine) | Indivior UK Limited | Concluded with an LOI | Opioid Use Disorder |
| Cystadrops (cysteamine) | Recordati Canada | Concluded with an LOI | corneal cystine crystal deposits |
| Libtayo (cemiplimab) | Sanofi Genzyme | Active Negotiation | Cutaneous Squamous Cell Carcinoma |
| Lenvima (lenvatinib) | Eisai Limited | Concluded with an LOI | hepatocellular carcinoma |
| Darzalex (daratumumab) | Janssen Inc. | Active Negotiation | Multiple Myeloma (newly diagnosed) |
| Lutathera (lutetium 177 dotatate) | Advanced Accelerator Applications | Concluded without agreement | Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) |
| Alunbrig (brigatinib) | Takeda Canada Inc. | Negotiations were not pursued | Non-Squamous Non-Small Cell Lung Cancer |
| Ninlaro (ixazomib) | Takeda Canada Inc. | Negotiations were not pursued | Multiple Myeloma |
| Verzenio (abemaciclib) | Eli Lilly Canada Inc. | Concluded without agreement | Advanced or Metastatic Breast Cancer |
| Vizimpro (dacomitinib) | Pfizer Canada ULC | Concluded without agreement | Non-Squamous Non-Small Cell Lung Cancer |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Negotiations were not pursued | Metastatic Urothelial Carcinoma (first line) |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Melanoma adjuvant therapy |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Non-Squamous Non-Small Cell Lung Cancer |
| Venclexta/rituximab (venetoclax/rituximab) | AbbVie Corporation | Concluded with an LOI | Chronic Lymphocytic Leukemia |
| Xalkori (crizotinib) | Pfizer Canada ULC | Concluded with an LOI | ROS1-positive advanced Non-Small Cell Lung Cancer |
| Ibrance/fulvestrant (palbociclib/fulvestrant) | Pfizer Canada ULC | Concluded with an LOI | Advanced or Metastatic Breast Cancer |
| Imfinzi (durvalumab) | AstraZeneca Canada Inc. | Concluded with an LOI | Non-small Cell Lung Cancer |
| Tafinlar/Mekinist (dabrafenib/trametinib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Melanoma adjuvant therapy |
| Trazimera (trastuzumab) | Pfizer Canada ULC | Concluded with an LOI | early breast cancer/metastatic breast cancer/metastatic gastric cancer |
| Herzuma (trastuzumab) | Teva Canada Limited | Concluded with an LOI | Metastatic Breast Cancer |
| Ogivri (trastuzumab) | BGP Pharma ULC | Concluded with an LOI | early breast cancer/metastatic breast cancer/metastatic gastric cancer |
| Opsumit (macitentan) | Actelion Pharmaceuticals Ltd. | Active Negotiation | Pulmonary Arterial Hypertension |
| Brilinta (ticagrelor) | AstraZeneca Canada Inc. | Concluded with an LOI | secondary prevention of atherothrombotic events |
| Triamcinolone Hexacetonide (triamcinolone hexacetonide) | Medexus Inc. | Concluded with an LOI | Subacute and chronic inflammatory joint diseases |
| Skyrizi (risankizumab) | AbbVie Corporation | Concluded with an LOI | Plaque psoriasis |
| Vyzulta (latanoprostene bunod) | Bausch Health, Canada Inc. | Concluded with an LOI | Open-angle Glaucoma |
| Blincyto (blinatumomab) | Amgen Canada Inc. | Concluded with an LOI | Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) |
| Folotyn (pralatrexate) | Servier Canada Inc. | Concluded with an LOI | Peripheral T-Cell Lymphoma |
| Botox (onabotulinumtoxin a) | Allergan Inc. | Active Negotiation | migraine, chronic |
| Xermelo (telotristat) | Ipsen Biopharmaceuticals | Negotiations were not pursued | carcinoid syndorme |
| Jublia (efinaconazole) | Bausch Health, Canada Inc. | Negotiations were not pursued | onychomycosis |
| Pifletro (doravirine) | Merck Canada Inc. | Concluded with an LOI | HIV Infection |
| Delstrigo (doravirine/lamuvidine/tenofovir disoproxil fumarate) | Merck Canada Inc. | Concluded with an LOI | HIV Infection |
| Cresemba (isavuconazole) | AVIR Pharma Inc. | Concluded with an LOI | Treatment of invasive aspergillosis and mucormycosis |
| Unituxin (dinutuximab) | United Therapeutics | Concluded with an LOI | neuroblastoma |
| Xtandi (enzalutamide) | Astellas Pharma Inc. | Concluded with an LOI | non-metastatic castrate resistant prostate cancer |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Melanoma adjuvant therapy |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Negotiations were not pursued | Hodgkin's Lymphoma |
| Radicava (edaravone) | Mitsubishi Tanabe Pharma Corporation | Concluded with an LOI | amyotrophic lateral sclerosis |
| Eucrisa (crisaborole) | Pfizer Canada ULC | Negotiations were not pursued | Atopic dermatitis |
| Brineura (cerliponase alfa) | BioMarin Pharmaceutical Inc. | Concluded with an LOI | neuronal ceroid lipofuscinosis type 2 |
| Kalydeco (ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | cystic fibrosis in patients with CFTR gating mutations or the R117H gating mutation |
| Zirabev (bevacizumab) | Pfizer Canada ULC | Concluded with an LOI | Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer |
| Spinraza (nusinersen) | Biogen Canada Inc. | Concluded with an LOI | Spinal Muscular Atrophy |
| Xeljanz (tofacitinib) | Pfizer Canada ULC | Concluded with an LOI | Ulcerative Colitis |
| Cabometyx (cabozantinib) | Ipsen Biopharmaceuticals | Concluded with an LOI | renal cell carcinoma |
| Mvasi (bevacizumab) | Amgen Canada Inc. | Concluded with an LOI | Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer |
| Ella (ulipristal acetate) | Allergan Inc. | Concluded with an LOI | prevention of pregnancy |
| Segluromet (ertugliflozin/metformin hydrochloride) | Merck Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Steglatro (ertugliflozin) | Merck Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Fulphila (pegfilgastrim) | BGP Pharma ULC | Concluded with an LOI | febrile neutropenia in non-myeloid malignancies |
| Xeljanz XR (tofacitinib) | Pfizer Canada ULC | Concluded with an LOI | Subacute and chronic inflammatory joint diseases |
| Humira (citrate-free) (adalimumab citrate-free) | AbbVie Corporation | Concluded without agreement | Multiple Indications |
| Ozempic (semaglutide) | Novo Nordisk Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Herceptin SC (trastuzumab) | Hoffmann-La Roche | Concluded without agreement | breast cancer |
| Tagrisso (osimertinib) | AstraZeneca Canada Inc. | Concluded with an LOI | first-line treatment of locally advanced or metastatic non-small cell cell lung cancer (NSCLC) |
| Lenvima (lenvatinib) | Eisai Limited | Negotiations were not pursued | advanced or metastatic, clear-cell renal cell carcinoma |
| Harvoni (ledipasvir/sofosbuvir) | Gilead Sciences Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Velphoro (sucroferric oxyhydroxide) | Vifor Fresenius Medical Care Renal Pharma | Concluded with an LOI | Hyperphosphatemia, end-stage renal disease |
| Soliqua (lixisenatide/insulin glargine) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Perjeta/Herceptin (pertuzumab/trastuzumab) | Hoffmann-La Roche | Negotiations were not pursued | early breast cancer |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Negotiations were not pursued | hepatocellular carcinoma |
| Daklinza (daclatasvir) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Januvia (sitagliptin phosphate) | Merck Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Yervoy/Opdivo (nivolumab/ipilimumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | renal cell carcinoma |
| Gazyva (obinutuzumab) | Hoffmann-La Roche | Negotiations were not pursued | Follicular Lymphoma |
| Erleada (apalutamide) | Janssen Inc. | Concluded with an LOI | non-metastatic castrate resistant prostate cancer |
| Xarelto (rivaroxaban) | Bayer Inc. | Concluded with an LOI | Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. |
| Ozurdex (dexamethasone) | Allergan Inc. | Negotiations were not pursued | Diabetic Macular Edema |
| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) | Gilead Sciences Canada Inc. | Concluded with an LOI | HIV infection |
| Fibristal (ulipristal acetate) | Allergan Inc. | Concluded with an LOI |
Intermittent treatment of moderate to severe signs and symptoms of uterine fibroids uterine fibroids |
| Alecensaro (alectinib) | Hoffmann-La Roche | Concluded with an LOI | Non-Small Cell Lung Cancer (First Line) |
| Praluent (alirocumab) | Sanofi-aventis Canada Inc. | Concluded without agreement | Atherosclerotic cardiovascular disease |
| Orkambi (lumacaftor/ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Negotiations were not pursued | Cystic Fibrosis, F508del CFTR mutation |
| Arbesda RespiClick (fluticasone propionate/salmeterol xinafoate) | Teva Canada Limited | Concluded without agreement | Asthma |
| Aermony Respiclick (fluticasone propionate) | Teva Canada Limited | Concluded without agreement | Asthma |
| Viberzi (eluxadoline) | Allergan Inc. | Negotiations were not pursued | Irritable Bowel Syndrome |
| Kanuma (sebelipase alfa) | Alexion Pharma GMBH | Concluded with an LOI | Lysosomal acid lipase deficiency |
| Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) | GlaxoSmithKline | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Mavenclad (cladribine) | EMD Serono a Division of EMD Inc. Canada | Concluded with an LOI | Relapsing-Remitting Multiple Sclerosis |
| Nucynta (tapentadol hydrochloride) | Paladin Labs Inc. | Negotiations were not pursued | Pain, severe |
| Fasenra (benralizumab) | AstraZeneca Canada Inc. | Concluded with an LOI | Eosinophilic Asthma |
| Dysport Therapeutic (abobotulinumtoxina) | Ipsen Biopharmaceuticals | Concluded with an LOI | Lower Limb Spasticity |
| Nitisinone (nitisinone) | Cycle Pharmaceuticals Ltd. | Concluded with an LOI | Hereditary Tyrosinemia Type 1 |
| Taltz (ixekizumab) | Eli Lilly Canada Inc. | Concluded with an LOI | Psoriatic Arthritis |
| Duodopa (levodopa/carbidopa) | AbbVie Corporation | Concluded with an LOI | Parkinson's Disease |
| Probuphine (buprenorphine) | Knight Therapeutics | Concluded with an LOI | Opioid Use Disorder |
| Ozanex (ozenoxacin) | Ferrer Internacional | Negotiations were not pursued | Impetigo |
| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) | Janssen Inc. | Concluded without agreement | HIV infection |
| Lonsurf (trifluridine/tipiracil) | Taiho Pharma Canada Inc. | Concluded with an LOI | Metastatic Colorectal Cancer |
| Besponsa (inotuzumab ozogamicin) | Pfizer Canada ULC | Concluded with an LOI | Acute Lymphoblastic Leukemia |
| Tecentriq (atezolizumab) | Hoffmann-La Roche | Concluded with an LOI | Non-small Cell Lung Cancer |
| Dupixent (dupilumab) | Sanofi Genzyme | Concluded with an LOI | Atopic dermatitis |
| Lapelga (pegfilgrastrim) | Apobiologix | Concluded with an LOI | Febrile Neutropenia |
| Siliq (brodalumab) | Valeant Canada | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Prevymis (letermovir) | Merck Canada Inc. | Concluded with an LOI | Cytomegalovirus infection prophylaxis |
| Juluca (dolutegravir/rilpivirine) | ViiV Healthcare | Concluded with an LOI | HIV infection |
| Akynzeo (netupitant/palonosetron) | Purdue Pharma | Concluded with an LOI | Nausea and vomiting (chemotherapy induced) prevention |
| Toujeo (insulin glargine injection) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Rituxan SC (rituximab) | Hoffmann-La Roche | Concluded with an LOI | Chronic Lymphocytic Leukemia |
| Kevzara (sarilumab) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Subacute and chronic inflammatory joint diseases |
| Dysport Therapeutic (abobotulinumtoxina) | Ipsen Biopharmaceuticals | Concluded with an LOI | Upper Limb Spasticity |
| Dysport Therapeutic (abobotulinumtoxina) | Ipsen Biopharmaceuticals | Concluded with an LOI | Cervical dystonia |
| Enstilar (calcipotriol/betamethasone) | LEO Pharma Inc. | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Classic Hodgkin's Lymphoma |
| Kisqali (ribociclib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Advanced or Metastatic Breast Cancer |
| Lartruvo (olaratumab) | Eli Lilly Canada Inc. | Concluded without agreement | Advanced Soft Tissue Sarcoma |
| Stivarga (regorafenib) | Bayer Inc. | Concluded with an LOI | Unresectable Hepatocellular Carcinoma |
| Alecensaro (alectinib) | Hoffmann-La Roche | Concluded with an LOI | Locally advanced or metastatic non-small cell lung cancer |
| Vectibix (panitumumab) | Amgen Canada Inc. | Negotiations were not pursued | Left Sided Metastatic Colorectal Cancer |
| Bavencio (avelumab) | EMD Serono a Division of EMD Inc. Canada | Concluded with an LOI | Metastatic Merkel Cell Carcinoma |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Metastatic Urothelial Carcinoma |
| Venclexta (venetoclax) | AbbVie Corporation | Concluded with an LOI | Chronic Lymphocytic Leukemia |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Concluded with an LOI | Hodgkin's Lymphoma |
| Ocrevus (ocrelizumab) | Hoffmann-La Roche | Concluded with an LOI | Primary Progressive Multiple Sclerosis |
| MDK-Nitisinone (nitisinone) | MendeliKABS Inc | Concluded with an LOI | Hereditary Tyrosinemia Type 1 |
| Monoprost (latanoprost) | Laboratoires Thea | Concluded without agreement | Glaucoma and Ocular Hypertension |
| Actemra (tocilizumab) | Hoffmann-La Roche | Concluded with an LOI | Giant Cell Arteritis |
| Vemlidy (tenofovir alafenamide) | Gilead Sciences Canada Inc. | Concluded without agreement | Hepatitis B |
| Ilaris (canakinumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Systemic juvenile idiopathic arthritis |
| Renflexis (infliximab) | Merck Canada Inc. | Concluded with an LOI | Rheumatic Conditions |
| Izba (travoprost) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Open-angle Glaucoma |
| Rexulti (brexpiprazole) | Otsuka Canada Pharmaceuticals | Concluded with an LOI | Schizophrenia |
| Galafold (migalastat) | Amicus Therapeutics | Concluded with an LOI | Fabry's Disease |
| Fiasp (insulin aspart) | Novo Nordisk Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 1 & 2 |
| Pomalyst (pomalidomide) | Celgene Inc. | Concluded with an LOI | Multiple Myeloma |
| Mictoryl Pediatric (propiverine hydrochloride) | Duchesnay Inc. | Concluded with an LOI | Overactive bladder |
| Jevtana (cabazitaxel) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Castrate resistant metastatic prostate cancer |
| Rosiver (ivermectin) | Galderma Canada Inc. | Concluded without agreement | Rosacea |
| Rydapt (midostaurin) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Acute Myeloid Leukemia |
| Lynparza (olaparib) | AstraZeneca Canada Inc. | Concluded with an LOI | Ovarian Cancer |
| Tagrisso (osimertinib) | AstraZeneca Canada Inc. | Concluded with an LOI | Non-Squamous Non-Small Cell Lung Cancer |
| Gazyva (obinutuzumab) | Hoffmann-La Roche | Concluded with an LOI | Follicular Lymphoma |
| Orfadin (nitisinone) | Sobi Canada Inc. | Concluded with an LOI | Hereditary Tyrosinemia Type 1 |
| Tremfya (guselkumab) | Janssen Inc. | Concluded without agreement | Psoriasis, moderate to severe plaque |
| Procysbi (cysteamine bitartrate) | Horizon Therapeutics Ireland DAC | Concluded with an LOI | Nephropathic cystinosis |
| Maviret (glecaprevir/pibrentasvir) | AbbVie Corporation | Concluded with an LOI | Chronic Hepatitis C |
| Movapo (apomorphine hydrochloride) | Paladin Labs Inc. | Concluded with an LOI | Parkinson's Disease |
| Vosevi (sofosbuvir/velpatasvir/voxilaprevir) | Gilead Sciences Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Spinraza (nusinersen) | Biogen Canada Inc. | Concluded with an LOI | Spinal Muscular Atrophy |
| Zykadia (ceritinib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Non-Squamous Non-Small Cell Lung Cancer |
| Viacoram (perindopril arginine/amlodipine) | Servier Canada Inc. | Concluded without agreement | Hypertension |
| Adlyxine (lixisenatide) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Repatha (evolocumab) | Amgen Canada Inc. | Concluded without agreement | Primary hyperlipidemia and mixed dyslipidemia |
| Ocrevus (ocrelizumab) | Hoffmann-La Roche | Concluded with an LOI | multiple sclerosis, relapsing |
| Tresiba (insulin degludec) | Novo Nordisk Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Stivarga (regorafenib) | Bayer Inc. | Negotiations were not pursued | Metastatic Colorectal Cancer |
| VPRIV (velaglucerase) | Shire Pharma Canada ULC | Concluded with an LOI | Gaucher disease |
| Elelyso (taliglucerase alfa) | Pfizer Canada ULC | Concluded with an LOI | Gaucher disease |
| Cerezyme (imiglucerase) | Sanofi Genzyme Canada | Concluded without agreement | Gaucher disease |
| Kyleena (levonorgestrel) | Bayer Inc. | Concluded with an LOI | Conception Control |
| Invega Trinza (paliperidone palmitate) | Janssen Inc. | Concluded with an LOI | Schizophrenia |
| Strensiq (asfotase alfa) | Alexion Pharma GMBH | Concluded with an LOI | pediatric-onset hypophosphatasia |
| Narcan (naloxone hydrochloride) | Adapt Pharma Operations Limited | Concluded with an LOI | Opioid Overdose |
| Methadose (methadone hydrochloride) | Mallinckrodt Canada ULC | Concluded without agreement | Opioid Dependence |
| Metoject (methotrexate) | Medexus Inc. | Concluded with an LOI | Rheumatic Conditions |
| Copaxone (glatiramer acetate) | Teva Canada Limited | Concluded without agreement | Clinically Isolated Syndrome |
| Botox (onabotulinumtoxin a) | Allergan Inc. | Concluded with an LOI | Multiple Indications |
| Faslodex (fulvestrant) | AstraZeneca Canada Inc. | Concluded without agreement | Locally Advanced or Metastatic Breast Cancer |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Classic Hodgkin's Lymphoma |
| Onivyde (irinotecan liposome) | Shire Pharma Canada ULC | Concluded without agreement | Metastatic Pancreatic Cancer |
| Yervoy/Opdivo (nivolumab/ipilimumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Metastatic Melanoma |
| Glatect (glatiramer acetate) | Pendopharm | Concluded with an LOI | Multiple Sclerosis, relapsing - remitting |
| Cerdelga (eliglustat) | Sanofi Genzyme Canada | Concluded without agreement | Gaucher disease |
| Ocaliva (obeticholic acid) | Intercept Pharma Canada | Concluded with an LOI | Primary biliary cholangitis |
| Caprelsa (vandetanib) | Sanofi Genzyme Canada | Concluded with an LOI | Medullary Thyroid Cancer |
| Erelzi (etanercept) | Sandoz Canada Inc. | Concluded with an LOI | Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis |
| Zinbryta (daclizumab beta) | Biogen Canada Inc. | Negotiations were not pursued | Multiple Sclerosis, relapsing |
| Darzalex (daratumumab) | Janssen Inc. | Concluded with an LOI | Multiple Myeloma |
| Lixiana (edoxaban) | Servier Canada Inc. | Concluded with an LOI | Venous thromboembolism, treatment and recurrence prevention |
| Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) | Gilead Sciences Canada Inc. | Concluded with an LOI | HIV infection |
| Lancora (ivabradine) | Servier Canada Inc. | Concluded with an LOI | Heart failure, NYHA class II or III |
| Fibristal (ulipristal acetate) | Allergan Inc. | Concluded without agreement | Uterine fibroids (signs and symptoms) - 2nd cycle pre-surgery |
| Mictoryl (propiverine hydrochloride) | Duchesnay Inc. | Concluded without agreement | Overactive bladder |
| Kevzara (sarilumab) | Sanofi-aventis Canada Inc. | Concluded without agreement | Subacute and chronic inflammatory joint diseases |
| Blincyto (blinatumomab) | Amgen Canada Inc. | Concluded with an LOI | Acute Lymphoblastic Leukemia |
| Actikerall (fluorouracil/salicylic acid) | Cipher | Concluded with an LOI | Hyperkeratotic actinic keratosis |
| Stelara (ustekinumab) | Janssen Inc. | Concluded without agreement | Crohn's disease |
| Lixiana (edoxaban) | Servier Canada Inc. | Concluded with an LOI | Non-valvular atrial fibrillation, prevention of stroke and systemic embolism |
| Blincyto (blinatumomab) | Amgen Canada Inc. | Concluded with an LOI | Pediatric Acute Lymphoblastic Leukemia (ALL) |
| Ravicti (glycerol phenylbutyrate) | Horizon Therapeutics Ireland DAC | Concluded with an LOI | Urea cycle disorders |
| Hemangiol (propranolol oral solution) | Pierre Fabre | Concluded with an LOI | Infantile hemangioma |
| Brivlera (brivaracetam) | UCB Canada Inc. | Concluded with an LOI | Epilepsy, partial-onset seizures |
| Ibrance (palbociclib) | Pfizer Canada ULC | Concluded with an LOI | Advanced Breast Cancer |
| Quinsair (levofloxacin) | Raptor Pharmaceuticals Inc. | Concluded with an LOI | Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections |
| Rituxan (rituximab) | Hoffmann-La Roche | Negotiations were not pursued | Acute Lymphoblastic Leukemia |
| Kyprolis (carfilzomib) | Amgen Canada Inc. | Concluded with an LOI | Multiple Myeloma |
| Uptravi (selexipag) | Actelion Pharmaceuticals Ltd. | Concluded with an LOI | Pulmonary Arterial Hypertension |
| Synjardy (empagliflozin/metformin) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Taltz (ixekizumab) | Eli Lilly Canada Inc. | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Kuvan (sapropterin dihydrochloride) | BioMarin Pharmaceutical Inc. | Concluded with an LOI | Phenylketonuria |
| Jardiance (empagliflozin) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Diabetes Mellitus, Type 2 with high cardiovascular risk |
| Invokamet (canagliflozin/metformin hydrochloride) | Janssen Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Brilinta (ticagrelor) | AstraZeneca Canada Inc. | Concluded without agreement | Prevention of atherothrombotic events with history of myocardial infarction |
| Descovy (emtricitabine/tenofovir alafenamide) | Gilead Sciences Canada Inc. | Concluded without agreement | HIV infection |
| Cosentyx (secukinumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Ankylosing spondylitis |
| Cosentyx (secukinumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Psoriatic Arthritis |
| Revestive (teduglutide) | Shire Pharma Canada ULC | Concluded with an LOI | Short Bowel Syndrome (SBS) |
| Praluent (alirocumab) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Primary hypercholesterolemia (non-familial and heterozygous familial) |
| Kyprolis (carfilzomib) | Amgen Canada Inc. | Concluded with an LOI | Multiple Myeloma |
| Trulicity (dulaglutide) | Eli Lilly Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Nucala (mepolizumab) | GlaxoSmithKline | Concluded with an LOI | Severe Eosinophilic Asthma |
| Vimizim (elosulfase alfa) | BioMarin Pharmaceutical Inc. | Concluded with an LOI | Mucopolysaccharidosis IVA (Morquio A syndrome) |
| Xolair (omalizumab) | Novartis Pharmaceuticals Canada Inc. | Concluded without agreement | Severe Persistent Asthma |
| Fycompa (perampanel) | Eisai Limited | Concluded with an LOI | Epilepsy, primary generalized tonic-clonic seizures |
| Pheburane (sodium phenylbutyrate) | Médunik | Concluded with an LOI | Urea cycle disorders |
| Naglazyme (galsulfase) | BioMarin Pharmaceutical Inc. | Negotiations were not pursued | Mucopolysaccharidosis VI |
| Repatha (evolocumab) | Amgen Canada Inc. | Concluded with an LOI | Primary hyperlipidemia and mixed dyslipidemia |
| Prolia (denosumab) | Amgen Canada Inc. | Concluded with an LOI | Osteoporosis in Men |
| Kalydeco (ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded without agreement | Cystic Fibrosis (CFTR gating mutations) |
| Truvada (emtricitabine/tenofovir disoproxil fumarate) | Gilead Sciences Canada Inc. | Negotiations were not pursued | HIV infection, pre-exposure prophylaxis |
| Strensiq (asfotase alfa) | Alexion Pharma GMBH | Concluded without agreement | pediatric-onset hypophosphatasia |
| Tafinlar/Mekinist (dabrafenib/trametinib) | Novartis Pharmaceuticals Canada Inc. | Negotiations were not pursued | Non-Small Cell Lung Cancer (with CNS metastases) |
| Giotrif (afatinib) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Advanced Non Small Cell Lung Cancer |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Squamos Cell Carcinoma of the Head and Neck |
| Simponi IV (golimumab) | Janssen Inc. | Concluded without agreement | Subacute and chronic inflammatory joint diseases |
| Stivarga (regorafenib) | Bayer Inc. | Concluded with an LOI | Gastrointestinal Stromal Tumours |
| Basaglar (insulin glargine) | Eli Lilly Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Mifegymiso (mifepristone and misoprostol) | Celopharma | Concluded with an LOI | Medical termination of pregnancy |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Non-small Cell Lung Cancer |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Non-small Cell Lung Cancer |
| Neupro (rotigotine) | UCB Canada Inc. | Concluded with an LOI | Parkinson's Disease |
| Brenzys (etanercept) | Merck Canada Inc. | Concluded with an LOI | Rheumatoid Arthritis and Ankylosing Spondylitis |
| Afinitor (everolimus) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Neuroendocrine tumours of Gastrointestinal or Lung origin |
| XigDuo (dapagliflozin/metformin hydrochloride) | AstraZeneca Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Humira (adalimumab) | AbbVie Corporation | Concluded with an LOI | Ulcerative Colitis |
| Avastin (bevacizumab) | Hoffmann-La Roche | Concluded with an LOI | Platinum-Resistant Ovarian Cancer |
| Avastin (bevacizumab) | Hoffmann-La Roche | Concluded with an LOI | Metastatic Colorectal Cancer |
| Sublinox (zolpidem tartrate) | Valeant Canada | Negotiations were not pursued | Insomnia, short-term treatment |
| Ninlaro (ixazomib) | Takeda Canada Inc. | Negotiations were not pursued | Multiple Myeloma |
| Eylea (aflibercept) | Bayer Inc. | Concluded with an LOI | Macular edema secondary to branch retinal vein occlusion |
| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) | Gilead Sciences Canada Inc. | Concluded with an LOI | HIV infection |
| Entresto (sacubitril/valsartan) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Heart failure, NYHA class II or III |
| Entyvio (vedolizumab) | Takeda Canada Inc. | Concluded with an LOI | Crohn's disease |
| Entyvio (vedolizumab) | Takeda Canada Inc. | Concluded with an LOI | Ulcerative Colitis |
| Epclusa (sofosbuvir/velpatasvir) | Gilead Sciences Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Sunvepra (asunaprevir) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Zepatier (elbasvir/grazoprevir) | Merck Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Otezla (apremilast) | Celgene Inc. | Concluded without agreement | Psoriatic Arthritis |
| Plegridy (peginterferon beta-1a) | Biogen Canada Inc. | Concluded with an LOI | Multiple Sclerosis, relapsing |
| Opsumit (macitentan) | Actelion Pharmaceuticals Ltd. | Concluded without agreement | Pulmonary Arterial Hypertension |
| Caprelsa (vandetanib) | Sanofi Genzyme Canada | Concluded without agreement | Medullary Thyroid Cancer |
| Jakavi (ruxolintib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Polycythemia vera |
| Alecensaro (alectinib) | Hoffmann-La Roche | Negotiations were not pursued | Non-Small Cell Lung Cancer (with CNS metastases) |
| Stelara (ustekinumab) | Janssen Inc. | Negotiations were not pursued | Psoriatic Arthritis |
| Votrient (pazopanib hydrochloride) | GlaxoSmithKline | Concluded with an LOI | Metastatic Renal Cell Carcinoma |
| Signifor (pasireotide diaspartate) | Novartis Pharmaceuticals Canada Inc. | Negotiations were not pursued | Cushing's disease |
| Samsca (tolvaptan) | Otsuka Canada Pharmaceuticals | Negotiations were not pursued | Hyponatremia, non-hypovolemic |
| Imbruvica (ibrutinib) | Janssen Inc. | Concluded with an LOI | Chronic Lymphocytic Leukemia |
| Grastofil (filgrastim) | ApoPharm Inc. | Concluded with an LOI | Prevention or treatment of neutropenia in various indications |
| Xolair (omalizumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Chronic Idiopathic Urticaria |
| Imbruvica (ibrutinib) | Janssen Inc. | Concluded with an LOI | Mantle Cell Lymphoma |
| Lenvima (lenvatinib) | Eisai Limited | Concluded with an LOI | Differentiated Thyroid Cancer |
| Mozobil (plerixafor) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Non-Hodgkin's Lymphoma and Multiple Myeloma |
| Rituxan SC (rituximab) | Hoffmann-La Roche | Concluded with an LOI | ALL for ritux sub-cu |
| Otezla (apremilast) | Celgene Inc. | Concluded without agreement | Psoriasis, moderate to severe plaque |
| Forxiga (dapagliflozin) | AstraZeneca Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Vectibix (panitumumab) | Amgen Canada Inc. | Concluded with an LOI | Metastatic Colorectal Cancer |
| Cotellic (cobimetinib) | Hoffmann-La Roche | Concluded with an LOI | Metastatic Melanoma |
| Esbriet (pirfenidone) | Hoffmann-La Roche | Concluded with an LOI | Pulmonary fibrosis (idiopathic, mild to moderate) |
| Ferriprox (deferiprone) | ApoPharm Inc. | Concluded with an LOI | Transfusional iron overload |
| Ofev (nintedanib) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Idiopathic pulmonary fibrosis (IPF) |
| Simponi SC (golimumab) | Janssen Inc. | Concluded with an LOI | Ulcerative Colitis |
| Arnuity Ellipta (fluticasone furoate) | GlaxoSmithKline | Concluded with an LOI | Asthma |
| Breo Ellipta (fluticasone furoate/vilanterol) | GlaxoSmithKline | Concluded with an LOI | Asthma |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Metastatic Renal Cell Carcinoma |
| Cosentyx (secukinumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Non-small Cell Lung Cancer |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Metastatic Melanoma |
| Lemtrada (alemtuzumab) | Sanofi Genzyme Canada | Concluded with an LOI | Relapsing-Remitting Multiple Sclerosis |
| Xeljanz (tofacitinib) | Pfizer Canada ULC | Concluded with an LOI | Subacute and chronic inflammatory joint diseases |
| Daklinza (daclatasvir) | Bristol Myers Squibb Canada Inc. | Concluded without agreement | Chronic Hepatitis C |
| Zydelig (idelalisib) | Gilead Sciences Canada Inc. | Negotiations were not pursued | Follicular Lymphoma |
| Jardiance (empagliflozin) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Diabetes Mellitus, Type 2 with high cardiovascular risk |
| Trajenta/Jentaduo (linagliptin (linagliptin/metformin)) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Nesina (alogliptin) | Takeda Canada Inc. | Negotiations were not pursued | Diabetes Mellitus, Type 2 |
| Prezcobix (darunavir/cobicistat) | Janssen Inc. | Concluded with an LOI | HIV Infection |
| Inspiolto Respimat (tiotropium/olodaterol) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Heart failure, NYHA class II |
| Spiriva Respimat (tiotropium bromide) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Byetta (exenatide) | AstraZeneca Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Blincyto (blinatumomab) | Amgen Canada Inc. | Concluded with an LOI | Acute Lymphoblastic Leukemia |
| Januvia (sitagliptin phosphate) | Merck Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Janumet (sitagliptin phosphate) | Merck Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Kazano (alogliptin/metformin) | Takeda Canada Inc. | Negotiations were not pursued | Diabetes Mellitus, Type 2 |
| Cimzia (certolizumab pegol) | UCB Canada Inc. | Concluded with an LOI | Ankylosing spondylitis |
| Butrans (buprenorphine) | Purdue Pharma | Concluded without agreement | Pain, persistent (moderate intensity) |
| Actemra SC (tocilizumab) | Hoffmann-La Roche | Concluded with an LOI | Subacute and chronic inflammatory joint diseases |
| Incruse Ellipta (umeclidinium) | GlaxoSmithKline | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Duaklir Genuair (aclidinium bromide/formoterol fumarate dihydrate) | AstraZeneca Canada Inc. | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Inflectra (infliximab) | Hospira Healthcare Corporation | Concluded with an LOI | Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis |
| Jinarc (tolvaptan) | Otsuka Canada Pharmaceuticals | Negotiations were not pursued | Autosomal dominant polycystic kidney disease (ADPKD) |
| Imbruvica (ibrutinib) | Janssen Inc. | Negotiations were not pursued | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| Darzalex (daratumumab) | Janssen Inc. | Negotiations were not pursued | Multiple Myeloma |
| Intuniv XR (guanfacine hydrochloride) | Shire Pharma Canada ULC | Negotiations were not pursued | Attention-deficit/hyperactivity disorder (ADHD) |
| Aptiom (eslicarbazepine acetate) | Sunovion Pharmaceuticals Canada Inc. | Concluded with an LOI | Epilepsy, partial-onset seizures |
| Simbrinza (brinzolamide/brimonidine) | Alcon | Concluded with an LOI | Glaucoma and Ocular Hypertension |
| Humira (adalimumab) | AbbVie Corporation | Negotiations were not pursued | Hidradenitis Suppurativa |
| Cyramza (ramucirumab) | Eli Lilly Canada Inc. | Concluded with an LOI | Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction (GEJ) Adenocarcinoma |
| Eliquis (apixaban) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Thromboembolic events (venous), treatment and prevention of recurrence |
| Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) | AbbVie Corporation | Concluded with an LOI | Chronic Hepatitis C |
| Abilify Maintena (aripiprazole) | Otsuka Canada Pharmaceuticals | Concluded with an LOI | Schizophrenia |
| Grastek (phleum pratense) | Merck Canada Inc. | Negotiations were not pursued | Allergy |
| Yondelis (trabectedin) | Janssen Inc. | Negotiations were not pursued | Metastatic Liposarcoma or Leiomyosarcoma |
| Fentora (fentanyl buccal) | Teva Canada Limited | Negotiations were not pursued | Pain (breakthrough), cancer (adults) |
| Fampyra (fampridine) | Biogen Canada Inc. | Negotiations were not pursued | Multiple Sclerosis, improve walking disability |
| Sylvant (siltuximab) | Janssen Inc. | Concluded with an LOI | Multicentric Castleman's Disease (MCD) |
| Anoro Ellipta (umeclidinium/vilanterol) | GlaxoSmithKline | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Revlimid (lenalidomide) | Celgene Inc. | Concluded with an LOI | Multiple Myeloma (newly diagnosed) |
| Rebif (interferon beta-1a) | EMD Serono a Division of EMD Inc. Canada | Concluded with an LOI | Clinically Isolated Syndrome |
| Ultibro Breezhaler (indacaterol/glycopyrronium) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Myrbetriq (mirabegron) | Astellas Pharma Inc. | Concluded with an LOI | Overactive Bladder |
| Tivicay (dolutegravir) | ViiV Healthcare | Concluded with an LOI | HIV Infection |
| Inspra (eplerenone) | Pfizer Canada ULC | Concluded with an LOI | Post myocardial infarction |
| Iclusig (ponatinib) | Paladin Labs Inc. | Concluded with an LOI | Chronic Myeloid Leukemia/Acute Lymphoblastic Leukemia |
| Sovaldi (sofosbuvir) | Gilead Sciences Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Breo Ellipta (fluticasone furoate/vilanterol) | GlaxoSmithKline | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Egrifta (tesamorelin) | Theratechnologies Inc. | Negotiations were not pursued | Lipodystrophy, HIV-infected patients |
| Edarbyclor (azilsartan medoxomil/chlorthalidone) | Takeda Canada Inc. | Negotiations were not pursued | Hypertension |
| Zydelig (idelalisib) | Gilead Sciences Canada Inc. | Concluded with an LOI | Chronic Lymphocytic Leukemia |
| Edarbi (azilsartan medoxomil) | Takeda Canada Inc. | Negotiations were not pursued | Hypertension |
| Dymista (azelastine/fluticasone propionate) | Meda Pharmaceuticals | Negotiations were not pursued | Seasonal allergic rhinitis |
| Tafinlar/Mekinist (dabrafenib/trametinib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Metastatic Melanoma |
| Cortiment (budesonide) | Ferring | Negotiations were not pursued | Ulcerative Colitis |
| Jetrea (ocriplasmin) | Alcon | Concluded with an LOI | Vitreomacular Adhesion |
| Constella (linaclotide) | Forest Laboratories Canada | Negotiations were not pursued | Irritable bowel syndrome with constipation |
| Xarelto (rivaroxaban) | Bayer Inc. | Concluded with an LOI | Thromboembolic events (venous), pulmonary embolism |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Metastatic Melanoma |
| Zykadia (ceritinib) | Novartis Pharmaceuticals Canada Inc. | Negotiations were not pursued | Non-Small Cell Lung Cancer (metastatic) |
| Bosulif (bosutinib) | Pfizer Canada ULC | Concluded with an LOI | Chronic Myeloid Leukemia |
| Bystolic (nebivolol) | Allergan Inc. | Negotiations were not pursued | Hypertension |
| Avastin (bevacizumab) | Hoffmann-La Roche | Concluded with an LOI | Cervical Cancer |
| Xalkori (crizotinib) | Pfizer Canada ULC | Concluded with an LOI | Non-Small Cell Lung Cancer (First Line) |
| Istodax (romidepsin) | Celgene Inc. | Concluded with an LOI | Peripheral T-Cell Lymphoma |
| Perjeta (Perjeta/Herceptin) (pertuzumab) | Hoffmann-La Roche | Negotiations were not pursued | Neoadjuvant Breast Cancer |
| Apprilon (doxycycline monohydrate) | Galderma Canada Inc. | Negotiations were not pursued | Rosacea |
| Nexavar (sorafenib) | Bayer Inc. | Negotiations were not pursued | Metastatic Progressive Differentiated Thyroid Carcinoma |
| Aloxi IV (palonosetron hydrochloride) | Eisai Limited | Negotiations were not pursued | Nausea and vomiting (chemotherapy induced) prevention |
| Aloxi (palonosetron hydrochloride) | Eisai Limited | Negotiations were not pursued | Nausea and vomiting (chemotherapy induced) prevention |
| Xtandi (enzalutamide) | Astellas Pharma Inc. | Concluded with an LOI | Metastatic Castration Resistant Prostate Cancer |
| Afinitor (everolimus) | Novartis Pharmaceuticals Canada Inc. | Negotiations were not pursued | Subependymal giant cell astrocytoma associated with tuberous sclerosis complex |
| Imbruvica (ibrutinib) | Janssen Inc. | Concluded with an LOI | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| Gazyva (obinutuzumab) | Hoffmann-La Roche | Concluded with an LOI | Chronic Lymphocytic Leukemia |
| Abraxane (nab-paclitaxel) | Celgene Inc. | Concluded with an LOI | Metastatic Pancreatic Cancer |
| Yervoy (ipilimumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | First Line Advanced Melanoma |
| Arzerra (ofatumumab) | GlaxoSmithKline | Negotiations were not pursued | Chronic Lymphocytic Leukemia |
| Afinitor (everolimus) | Novartis Pharmaceuticals Canada Inc. | Negotiations were not pursued | renal angiomyolipoma associated with tuberous sclerosis complex (TSC) |
| Adempas (riociguat) | Bayer Inc. | Negotiations were not pursued | Pulmonary Arterial Hypertension (WHO group 1) |
| Abilify (aripiprazole) | Bristol Myers Squibb Canada Inc. | Negotiations were not pursued | Major Depressive Disorder |
| Pomalyst (pomalidomide) | Celgene Inc. | Concluded with an LOI | Multiple Myeloma |
| Zaltrap (aflibercept) | Regeneron | Negotiations were not pursued | Metastatic Colorectal Cancer |
| Effient (prasugrel) | Eli Lilly Canada Inc. | Concluded with an LOI | Acute Coronary Syndrome |
| Seebri (glycopyrronium bromide) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) | Gilead Sciences Canada Inc. | Concluded with an LOI | HIV infection |
| Stivarga (regorafenib) | Bayer Inc. | Concluded with an LOI | Gastrointestinal Stromal Tumours |
| Abilify (aripiprazole) | Bristol Myers Squibb Canada Inc. | Concluded without agreement | Schizophrenia and Related Psychotic Disorders |
| Tysabri (natalizumab) | Biogen Canada Inc. | Concluded with an LOI | Relapsing-Remitting Multiple Sclerosis |
| Revlimid (lenalidomide) | Celgene Inc. | Concluded with an LOI | Multiple Myeloma |
| Giotrif (afatinib) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Advanced Non Small Cell Lung Cancer |
| Mekinist (trametinib) | GlaxoSmithKline | Concluded with an LOI | Metastatic Melanoma |
| Onbrez (indacaterol) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Gilenya (fingolimod) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Multiple Sclerosis |
| Tafinlar (dabrafenib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Metastatic Melanoma |
| Xarelto (rivaroxaban) | Bayer Inc. | Concluded with an LOI | Atrial fibrillation, stroke prevention |
| Pradaxa (dabigatran etexilate) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Atrial fibrillation prevention of stroke and systemic embolism |
| Victoza (liraglutide) | Novo Nordisk Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Humira (adalimumab) | AbbVie Corporation | Concluded with an LOI | Hidradenitis Suppurativa |
| Cinqair (reslizumab) | Teva Canada Limited | Concluded without agreement | Eosinophilic Asthma |
| Erivedge (vismodegib) | Hoffmann-La Roche | Concluded with an LOI | Advanced Basal Cell Carcinoma |
| Kadcyla (trastuzumab emtansine) | Hoffmann-La Roche | Concluded with an LOI | Metastatic Breast Cancer |
| Alimta (pemetrexed) | Eli Lilly Canada Inc. | Concluded with an LOI | Advanced Non-Squamous Non Small Cell Lung Cancer |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Concluded with an LOI | Systemic Anaplastic Large Cell Lymphoma |
| Xiaflex (collagenase clostridium histolyticum) | Auxillium Pharmaceuticals Inc. | Negotiations were not pursued | Dupuytren’s contracture with a palpable cord |
| Xgeva (denosumab) | Amgen Canada Inc. | Negotiations were not pursued | Prevention of skeletal-related events due to bone metastases from breast cancer |
| Zytiga (abiraterone) | Janssen Inc. | Concluded with an LOI | Metastatic Castration Resistant Prostate Cancer |
| Victoza (liraglutide) | Novo Nordisk Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Erbitux (cetuximab) | Eli Lilly Canada Inc. | Negotiations were not pursued | Metastatic Colorectal Cancer |
| Votrient (pazopanib hydrochloride) | GlaxoSmithKline | Concluded with an LOI | Metastatic Renal Cell Carcinoma |
| Technivie (ombitasvir/paritaprevir/ritonavir) | AbbVie Corporation | Concluded without agreement | Chronic Hepatitis C (genotype 4) |
| Soliris (eculizumab) | Alexion Pharma GMBH | Concluded without agreement | Atypical Hemolytic Uremic Syndrome |
| Inlyta (axitinib) | Pfizer Canada ULC | Concluded with an LOI | Metastatic Renal Cell Carcinoma |
| Perjeta/Herceptin (pertuzumab/trastuzumab) | Hoffmann-La Roche | Concluded with an LOI | Metastatic Breast Cancer |
| Afinitor (everolimus) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Pancreatic Neuroendocrine Tumors |
| Jadenu (deferasirox) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Chronic Iron Overload |
| Rosiver (ivermectin) | Galderma Canada Inc. | Concluded without agreement | Rosacea |
| Sovaldi (sofosbuvir) | Gilead Sciences Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Xtandi (enzalutamide) | Astellas Pharma Inc. | Concluded with an LOI | Metastatic Castration Resistant Prostate Cancer |
| Metadol-D (methadone hydrochloride) | Paladin Labs Inc. | Concluded with an LOI | Opioid Dependence |
| Revolade (eltrombopag) | GlaxoSmithKline | Negotiations were not pursued | Thrombocytopenia associated with chronic hepatitis c infection |
| Picato (ingenol mebutate) | LEO Pharma Inc. | Negotiations were not pursued | Actinic keratosis |
| Inflectra (infliximab) | Hospira Healthcare Corporation | Concluded with an LOI | Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn’s disease and Ulcerative Colitis |
| Replagal (agalsidase alfa) | Shire Pharma Canada ULC | Concluded with an LOI | Fabry's Disease |
| Fabrazyme (agalsidase beta) | Sanofi Genzyme Canada | Concluded with an LOI | Fabry's Disease |
| Orkambi (lumacaftor/ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Negotiations were not pursued | Cystic Fibrosis, F508del CFTR mutation |
| Jakavi (ruxolintib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Myelofibrosis |
| Tobi Podhaler (tobramycin) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Pseuodomonas aeruginosa infections in cystic fibrosis |
| Campral (acamprosate calcium) | Mylan Pharmaceuticals LLC | Concluded without agreement | Alcohol Abstinence |
| Sutent (sunitinib malate) | Pfizer Canada ULC | Concluded with an LOI | Pancreatic Neuroendocrine Tumors |
| Zaxine (rifaximin) | Lupin Pharma Canada Limited | Concluded with an LOI | Hepatic Encephalopathy |
| Juxtapid (lomitapide) | Aegerion Pharmaceuticals Canada Ltd. | Negotiations were not pursued | Homozygous Familial Hypercholesterolemia |
| Tykerb & Letrozole (lapatinib) | GlaxoSmithKline | Negotiations were not pursued | Metastatic Breast Cancer |
| Xalkori (crizotinib) | Pfizer Canada ULC | Concluded with an LOI | Non-Squamous Non-Small Cell Lung Cancer |
| Fibristal (ulipristal acetate) | Allergan Inc. | Concluded with an LOI | Uterine fibroids (signs and symptoms) |
| Firazyr (icatibant) | Shire Pharma Canada ULC | Concluded with an LOI | Hereditary Angioedema |
| Invokana (canagliflozin) | Janssen Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Diacomit (stiripentol) | Biocodex SA | Concluded with an LOI | Dravet Syndrome |
| Triumeq (dolutegravir/abacavir/lamivudine) | ViiV Healthcare | Concluded with an LOI | HIV Infection |
| Eylea (aflibercept) | Bayer Inc. | Concluded with an LOI | Age-Related Macular Degeneration |
| Ibavyr (ribavirin) | Pendopharm | Concluded with an LOI | Chronic Hepatitis C |
| Halaven (eribulin) | Eisai Limited | Concluded with an LOI | Metastatic Breast Cancer |
| Remicade (infliximab) | Janssen Inc. | Concluded with an LOI | rheumatoid arthritis, ulcerative colitis and Crohn’s disease |
| Harvoni (ledipasvir/sofosbuvir) | Gilead Sciences Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Advair (salmeterol xinafoate/fluticasone propionate) | GlaxoSmithKline | Concluded with an LOI | Chronic Obstructive Pulmonary Disease and asthma |
| Valtrex (valacyclovir) | GlaxoSmithKline | Concluded with an LOI | Specific Viral Infections |
| Adempas (riociguat) | Bayer Inc. | Concluded with an LOI | Pulmonary hypertension, chronic thromboembolic |
| Onglyza (saxagliptin) | AstraZeneca Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Soliris (eculizumab) | Alexion Pharma GMBH | Concluded with an LOI | Paroxysmal nocturnal hemoglobinuria (PNH) |
| Aubagio (teriflunomide) | Sanofi Genzyme Canada | Concluded with an LOI | Multiple Sclerosis, relapsing |
| Orencia (abatacept) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Subacute and chronic inflammatory joint diseases |
| Galexos (simeprevir) | Janssen Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Esbriet (pirfenidone) | Hoffmann-La Roche | Concluded with an LOI | Pulmonary fibrosis (idiopathic, mild to moderate) |
| Tudorza Genuair (aclidinium bromide) | AstraZeneca Canada Inc. | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Kalydeco (ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | Cystic Fibrosis patients (G551D mutation) |
| Lodalis (colesevelam hydrochloride) | Valeant Canada | Concluded with an LOI | Hypercholesterolemia |
| Tecfidera (dimethyl fumarate) | Biogen Canada Inc. | Concluded with an LOI | Multiple Sclerosis, relapsing |
| Treanda (bendamustine hydrochloride) | Lundbeck Canada Inc. | Concluded with an LOI | Non-Hodgkin's Lymphoma |
| Oralair (grass pollen allergen extract) | Paladin Labs Inc. | Concluded with an LOI | Allergic Rhinitis |
| Benlysta (belimumab) | GlaxoSmithKline | Negotiations were not pursued | Systemic lupus erythematosus |
| Mozobil (plerixafor) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Non-Hodgkin's Lymphoma and Multiple Myeloma |
| Yervoy (ipilimumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Advanced Melanoma |
| Dificid (fidaxomicin) | Optimer Pharmaceuticals | Concluded with an LOI | Clostridium difficile infection |
| Eliquis (apixaban) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Thromboembolic events prevention, (atrial fibrillation) |
| Replagal (agalsidase alfa) | Shire Pharma Canada ULC | Concluded with an LOI | Fabry's Disease |
| Fabrazyme (agalsidase beta) | Sanofi Genzyme Canada | Concluded with an LOI | Fabry's Disease |
| Brilinta (ticagrelor) | AstraZeneca Canada Inc. | Concluded with an LOI | Thrombotic events in Acute Coronary Syndromes, Prevention |